Business
Distribution of Verici Dx shares by EKF
Distribution of Verici Dx shares by EKF.
About this update from Verici Dx Plc
[{"type":"text","content":"\n \n \n \n Verici Dx plc\n \n \n \n \n (\"Verici Dx\" or the \"Company\")\n \n \n \n \n \n \n \n \n \n Distribution of Verici Dx shares by EKF Diagnostics Holdings plc\n \n \n \n \n \n \n \n \n Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\n notes the announcement made by EKF Diagnostics Holdings PLC (\"EKF\") this morning (RNS 3845P), declaring the distribution of its Verici Dx Investment Shares to Relevant EKF Shareholders via a distribution in specie.\n \n \n \n \n \n These shares comprise of\n 9,098,611 ordinary shares in Verici Dx of £0.001 each and are subject to a Lock-up Period of 365 days from transfer.\n \n \n \n \n \n \n Full details can be seen in the EKF announcement here:\n \n \n \n \n https://www.londonstockexchange.com/news-article/EKF/distribution-of-shares-in-verici-dx-plc/15501862\n \n \n \n \n Capitalised terms in this announcement carry the same definitions as in the EKF announcement.\n \n \n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n \n \n \n \n \n \n Verici Dx\n \n \n \n \n \n \n \n www.v\n \n \n ericidx\n \n \n .com\n \n \n \n \n \n \n \n \n Sara Barrington, CEO \n \n \n \n \n \n Via Walbrook PR\n \n \n \n \n \n \n \n Julian Baines, Chairman\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Singer Capital Markets (Nominated Adviser & Broker)\n \n \n \n \n \n \n Tel: 020 7496 3000\n \n \n \n \n \n \n \n Aubrey Powell / Kailey Aliyar / Rachel Hayes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Walbrook PR Limited\n \n \n \n \n \n \n Tel: 020 7933 8780\n \n or \n \n \n [email protected]\n \n \n \n \n \n \n \n \n Paul McManus / Sam Allen\n \n \n \n \n Mob: 07980 541 893 / 07502 558 258\n \n \n \n \n \n \n \n \n \n \n \n \n About Verici Dx plc\n \n www.vericidx.com\n \n \n \n Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway s...